SUBJECT INDEX

A

Acetaminophen toxicity
  metallothionein-mediated protection against, 283
N-Acetylserotonin
  melatonin synthesis and, 54–56
  molecular cloning of, 55–56
Adenylyl cyclase, 343, 345–46, 353–54
  β-AR–mediated stimulation of, 345
  expression and function in congestive heart failure, 353–54
  isoforms, 345–46
β-Adrenergic receptor pathway
  cardiac, 343–48
    subtype, 344
  congestive heart failure and, 348–55
Ah receptor nuclear translocator (Arnt), 105–19
  CYP1A1 gene regulation and, 105–19
Allylamine
  oxidant-induced atherosclerosis and, 234–59
Aminoguanidine
  nitric oxide synthase inhibition, 200
AMPA receptors
  glutamate receptor expression and, 221–22, 234–36
Antioxidant response element (ARE), 83–88, 254–56
  AP-1 and, 85
  structure, 84–85
Antioxidants, 67–68, 83–88
Antisense inhibition, 175, 184–85
Antisense technology
  dopaminergic receptor function, 315, 317–18, 323–25, 329–30, 332–37
AP-1 activation
  antioxidant response-element and, 85
  reactive oxygen species and, 72–77, 79–80
    arachidonate metabolism and, 74–75
    Ca^{2+} mobilization and, 74–75
    map kinases and, 75–76
  redox regulation of, 73–74
Apoptosis
  cytotoxicity of short-chain alcohols and, 127–42
Arachidonic acid, 160, 175–85, 446–47
  excitatory amino acid transporter uptake and, 446–47
Arachidonic acid metabolism, 175–85
  phospholipase A_2 regulation and, 175–85
Arachinoic acid metabolites, 74–75
L-Arginine analogues, 191, 197–200
  nitric oxide synthase inhibition and, 197–200, 202–3, 208
Aromatic (aryl) hydrocarbon
  CYP1A1 gene regulation and, 105–19
  ligands, 115–16
  receptor (AhR), 105–19
  See also Ah receptor nuclear translocator
Arotinoids, 413–14
Aryl hydrocarbon receptor (AhR), 246, 252–54
  oxidant-induced atherosclerosis and, 246, 252–54
Ascorbate, 68
Aspartate, 431–32, 435, 447
Astrocytes, 151–61
  astrocytic swelling, 152–61
    amino acid release and, 160
    electrolyte release and, 160
    mechanism of, 155–59
    MeHg-induced, 152–54
    taurine release and, 160
  modulation of neurotoxicity and, 152–55
Atherosclerosis, 243–59
  oxidant-induced, 243–59
    AhR receptor and, 246, 252–54
    allylamine exposure and, 246–47, 256–59
    benzo(a)pyrine exposure and, 244–46
    c-Ha-ras gene and, 243, 248, 251–56
    extracellular matrix and, 250, 256–58
    integrins, 250–51
    mechanisms of, 244–47
    oncogenes and, 247–48
    osteopontin and, 249, 256–58
    platelet-derived growth factor and, 247–48
    vascular smooth muscle cell proliferation in, 244–47
ATP hydrolysis, 361, 367–84
  drug transport and, 367–84
    coupled to drug binding, 370–71
    cyclosporin A and, 368
    p-glycoprotein and, 361–90

B

Barbituates
  cytochrome P-450 gene expression and, 1, 3–4, 11–12
Basic helix-loop-helix/Per-Arnt Sim
  See bHLH/PAS proteins
Benzo(a)pyrene (Bap)
  vascular injury from, 243–46, 251
bHLH/PAS proteins, 104–19
  aromatic (aryl) hydrocarbons receptors (AhR) and, 106–19
  heterodimerization, 108
  signaling systems, 109, 112–15
Butanol, 127, 130

C

Cadmium toxicity
  metallothionein and protection against, 267–68, 275–79
Caffeine
  acetaminophen oxidation and, 11
cAMP
  cardiac β-adrenergic receptor pathway and, 343, 345, 348
cAMP response element (CRE)
  night specificity of melatonin synthesis and, 57–58
cAMP response element binding protein (CREB)

night specificity of melatonin synthesis and, 57–58
cCAMP reponse element modulators (CREM)
night specificity of melatonin synthesis and, 57–58
Cancer
cell cycle regulation and, 295, 301–6
therapeutic modulation of, 303–6
Cancer chemotherapy
chemosensitizers, 361, 367–69, 374–82
cochicine, 375
peptides, 382–83
phenethiazines, 380–81
phenoxazine, 379
prefafenone-related compounds, 379
prenylcysteines, 381–82
reserpine, 378
staurosporine, 378
verapamil, 369, 375–77
multidrug resistance and, 361–90
Carbon tetrachloride toxicity
metallothionein-mediated protection, 282
β-Carotene, 401, 407, 420–21
Catecholamine, 343, 348
β-AR–mediated damage and necrosis of cardiac tissue and, 348
Catechol O-methyltransferase (COMT) methylation, 21–29, 44–45
pharmacogenetics of, 21–29
Cell cycle, 295–307
therapeutic modulation of, 303–6
Cell proliferation
short-chain alcohols and, 127, 139–42
Cellular RA-binding proteins (CRABP), 408–9
Cellular retinol-binding protein (CRBP), 407–9
c-Ha-ras gene
oxidant-induced atherogenesis and, 243, 245, 248, 251–56
Chemical inhibition
phospholipid A, 175, 181–84
Chemosensitizer
reversal of multidrug resistance by, 361, 367–69, 374–82
Chloroquine, 380
Chromatin structure, 110, 117–19
Cip Kip family, 299
Circadian rhythms
melatonin synthesis and, 58–62
hydroxyindole-O-methyltransferase and, 54–55
serotonin N-acetyltransferase and, 53–55, 62
pineal gland and, 53–62
suprachiasmatic nucleus and, 57, 60, 61
See also Melatonin; Pineal gland
Cisplatin toxicity
metallothionein-mediated protection against, 282
L-Citrulline analogues, 200
Colchicine, 375
Cone-rod homeobox, 53
pineal transcription regulatory element and, 53
Congestive heart failure
adenylyl cyclase expression and function in, 353–54
β-AR expression and function in, 348–50
G-protein receptor kinases expression and function in, 350–51
GTP-binding protein expression and function in, 351–53
Cooperativity, 1, 9–11
cytochrome P-450 3A4 system and, 1, 9–11
heterotropic, 9–11
homotropic, 9–11
Copper homeostasis
metallothionein and, 273–74
Cotransport, 431, 436–40
CRX, 57
Cyclin-dependent kinase inhibitors, 295, 299–301
Cyclins, 295–307
mammalian, 296
progression through cell cycle, 297–99
Cyclosporin A
drug transport and, 368–69
CYP1A1 gene regulation, 103–19
Cytochrome P4501A1 induction, 103–19
aromatic (aryl) hydrocarbon receptor (AhR) and, 105
in intact cells, 110
polycyclic aromatic hydrocarbon (PAH) induced disease and, 104–19
susceptibility to cancer and, 116–17
Cytochrome P-4502E1, 132–33
short-chain alcohols and, 132–33
Cytochrome P-450 3A4, 1–12
catalysis
cooperativity, 9–11
mechanisms, 6–11
selectivity, 6
drug substrates for, 7
gene expression regulation, 1–4
barbituates and, 1, 3–4
glucocorticoids and, 1, 4, 11
rifampicin and, 1, 3–4
human subfamily members, 2
study methods, 4–5
Cytochrome P450 reductase, 193–94

D

δ2 subunit, 234
Diabetes, 191, 208–9
potential therapeutic use of selective nitric oxide synthase inhibitors for, 208–9
Dopaminergic receptor
classification and pharmacology, 314–15
Dopaminergic receptor function, 313–37
antisense technology, 315–37
D_1 receptor, 317–18, 323
D_2 receptors, 323–25, 329
D_3 receptors, 329–30
D_4 receptors, 332–33
D_5 receptors, 334–35
homologous recombination, 316–37
D_1 receptor, 318–23
D_2 receptors, 325–29
D_3 receptors, 330–32
D_4 receptors, 333–34
D_5 receptors, 335–36
transgenic approach, 315
Drug transport, 361–90
ATP hydrolysis and, 367–84
p-glycoprotein and, 361–90
catalytic cycle, 373–74
multidrug resistance and, 361–90

E

Eicosanoids
biosynthesis of, 175–77
inflammation and, 175–77
Embryogenesis, 399–421
teratogenesis and developmental stage of

embryo at exposure and, 402–3
dose-response relationship and, 406
functional deficits and, 404–5
genetic factors and, 400–2
rate and extent of exposure and, 405–6
teratogenic mechanisms, 403–4
vitamin A and, 399–421
Ethanol
cytotoxicity of, 127–42
cell prolifertion and, 139–42
dual effect on DNA synthesis, 141
fatty acid ethyl esters and, 127, 130–31
See also Short-chain alcohols
Etretinate, 404, 419–20
Eucaryotic cell cycle, 295–307
Excitatory amino acid (EAA) transporters, 431–49
gene family, 431–34
ionic dependence of, 436–39
ischemia and, 448–49
ligand-gated channels, 439–40
localization, 443–44
neurodegenerative disease and, 448
pharmacology of, 434–35
regulation, 445–47
structural motifs, 435–36
structure/function analysis, 442–43
synaptic signaling and uptake, 444–45
as therapeutic targets, 448–49
transmembrance topology, 440–41
Extracellular matrix
oxidant-induced atherosclerosis and, 243, 256–58

F

Fatty acid ethyl esters
cytotoxic effects of, 127, 130–31
Fenton reaction, 69
Fluoroacetate, 155
Fluorocitrate, 155
Free radical scavenge
metallotheonein as, 267, 279–83
adridymycin and, 280–81
hydrogen peroxide and, 280
paraquat and, 280–81
radiation and, 281
tert-butylhydroperoxide and, 280

G

Genetic polymorphism
cytochrome P-450 3A4 and, 1–12
methyl conjugation and pharmacogenetics of, 19–46
N-methylation, 39–44
O-methylation, 21–29
S-methylation, 30–39
Glial cells, 151–68
Glucocorticoid regulatory element, 1, 4
Glucocorticoids
cytochrome P-450 3A4 expression and, 1, 4, 11
Glutamate, 431–49
(2S, 4R)-4-methylglutamate, 435
Glutamate receptor expression, 221–36
AMPA receptors and, 222, 231, 234–36
genetically altered, 231–36
kainate receptors and, 222, 231–36
NMDA receptors and, 222, 231–34
translational regulation of, 230–31
transcriptional regulation of, 223–29
Glutamate transporters, 431–49
ionic dependence of, 436–39
ligand-gated channels, 439–40
localization, 443–44
pharmacology, 434–35
regulation, 445–47
structural motifs, 435–36
structure/function analysis, 442–43
synaptic signaling and uptake, 444–45
as therapeutic targets, 448–49
ischemia, 448–49
neurodegenerative disease, 448
Glutathione, 3, 68
chemosensitizers, 361, 367–69, 374–82
colchicine, 375
peptides, 382–83
phenothiazines, 380–81
phenoxazine, 379
prenylcysteines, 381–82
profafenone-related compounds, 379
quinacrine and chloroquine, 379
reserpine, 378
staurosporine, 378
verapamil, 369, 375–77
cytochrome P-450 3A4 and, 3
P-Glycoprotein (P-gp), 361–91
ATPase activity of, 369–70
as ATPase-driven efflux pump, 371–72
mechanism of action, 383–85
multiple drug resistance and, 361–81
mutational analysis, 363–67
protection against xenobiotics and, 385–86
substrates, 367
therapeutic implications of pharmacologic inhibition, 388–90
vaccinia virus-based transient expression system for characterization of, 367
G protein, 343, 345–53
cardiac β-adrenergic receptor-mediated expression and function in congestive heart failure, 351–53
G protein receptor kinases (GRKs), 343, 346–51
cardiac β-adrenergic receptor pathway and, 343, 346, 350–51
expression and function in congestive heart failure, 350–51
Guanidine, 198, 200, 201
mercapto-alkyl-guanidine nitric oxide synthase inhibition and, 198, 201

H

Heterologous expression, 1
Histamine N-methyltransferase (HNMT), 21–22, 39–44
pharmacogenetics of, 39–44
Homologous recombination
dopaminergic receptor function, 316, 318–23, 325–29, 330–37
Hydroxyindole-O-methyl-transferase (HIOMT)
melatonin production and, 54–55

I

Indazoles
  nitric oxide synthase inhibition and, 198, 201, 203–4, 207
  7-nitroindazole, 198, 201, 203–4, 207
Inducible cAMP early repressor
  night specificity of melatonin synthesis and, 57–58
Inflammation, 175–85, 191, 205–7
  eicosanoid biosynthesis and, 175–77
  phospholipase A_2 and, 175–77
  phospholipid *sn-2* fatty acyl bonds and, 176
  therapeutic use of selective nitric oxide synthase inhibitors for, 205–7
INK4 family, 300–1
Integrins
  oxidant-induced atherosclerosis and, 250–51
Intercellular adhesion molecule-1 (ICAM-1), 79–80
Iodo-melatonin, 59
Ischemia
  excitatory amino acid transporters and, 448–49
bis-Isothioureas
  nitric oxide synthase inhibition, 200–1

K

Kainate receptors
  glutamate receptor expression and, 222, 231, 234–35
Knockout mice
  glutamate receptor expression and, 231–36
Krebs cycle, 155–56

L

Lipid second messenger, 175
Lysophosphatidic acid, 129–30

M

mdr genes, 362, 387–88
Melatonin, 53–62
  biosynthesis of, 54–55
    CRX and, 57
    hydroxyindole-O-methyltransferase and, 54–55
    knockouts, 53, 60
    night specificity of, 57–58
    pineal gland and, 53–62
    pineal regulation element and, 53, 56
    pineal specificity, 56–57
    serotonin and, 54–55
    serotonin N-acetyltransferase and, 54–55
    suprachiasmatic nucleus and, 57, 60
  iodo-, 59
  pharmacologic actions, 60–62
  potential therapeutic actions, 60–62
  role in mammals, 58–60
  See also Circadian rhythms; Pineal gland
Meningitis
  potential therapeutic use of selective nitric oxide synthase inhibitors for, 209
Menke's disease, 274
6-Mercaptopurine (6-MP), 20, 29
Mercury toxicity
  metallothionein and protection against, 279
Metabolic state
  mitochondria and, 127, 131, 133–39, 142
    cytotoxicity of short-chain alcohols and, 127, 131, 133–39, 142
Metallothionein, 267–86
  essential metal homeostasis and, 272–74
    copper and, 273–74
    zinc and, 272–73
  gene regulation, 270–71
  protection against metal toxicity, 154, 275–79
  protection against neurodegenerative disease, 283–84
  protection against oxidative stress
  protein degradation regulation, 271–72
  as potential scavenger of brain mercury, 154
  as reactive oxygen species trap, 279–83
  structure, 268–70
  transgenic and knockout animals, 267
Metal response element–binding transcription factor 1 (MTF-1), 80–83
  reactive oxygen and activation of, 80–83
Metal responsive elements, 80–83, 270
Methanol
  cytotoxicity of, 127–42
  See also Short-chain alcohols
Methylation pharmacogenetics, 19–46
  N-methylation, 39–44
  O-methylation, 21–29
  S-methylation, 29–39
Methyl conjugation, 19–46
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), 154–55
  neurotoxicity induced by, 154–55
Methyltransferases (MT), 19–46
  catechol O-, 19, 21–29, 44–45
  histamine N-, 21–22, 39–44
  nicotinamide N-, 19, 22
  phenylethanolamine N-, 19, 39
  thiol, 19, 22
  thiopurine, 20, 22, 29–38
Microglia
  neurotoxicity and, 151, 161–66
Migraine
  potential therapeutic use of selective nitric oxide synthase inhibitors for, 207
Mitochondria, 67–69, 131–39
  cytotoxic effects of short-chain alcohols
    ATP synthesis and, 134
    cell death and, 133–39
    decreased protein synthesis and, 135
    electron transport chain, 133–35
    fatty acid ethyl esters and, 131
    metabolism and, 133–39
    phosphorylation coupling and, 133, 136–37
  reactive oxygen species formation and, 68–69
    mitochondrial electron transport and, 69
Multidrug resistance, 361–90
  chemosensitizers and reversal of, 361, 367–69
Multidrug transporter, 361–90
  See also P-Glycoprotein

N

NF-κ > B, 77–79
Neurodegeneration
  potential therapeutic use of selective nitric oxide inhibitors for, 204–5
Neurodegenerative disease
  excitatory amino acid transporters and, 448–49
Neuroglia, 151–68
Neurotoxicity, 151–68
  astrocytic swelling and, 152–61
    amino acid release and, 160
    mechanism of, 155–59
    MeHg-induced, 152–54
    taurine release and, 160
  fluoroacetate-induced, 155
  fluorocitrate-induced, 155
  MeHg-induced, 152–54
  microglia and, 151, 161–66
  MPTP-induced, 154–55
  neuroglia and, 151–68
  Schwann cells and, 151, 166–68
Nicotinamide adenine dinucleotide, 43
Nicotinamide N-methyltransferase (NNMT), 19, 40, 44–45
Nifedipine oxidation, 1, 3–4
Nitric oxide, 67, 191–211
  diabetes and, 208–9
  function and pathologies of, 191–92
  inflammation and, 205–7
  mechanisms of action, 196–97
  meningitis and, 209
  migraine and, 207–8
  neurodegeneration and, 204–5
  nociception and, 207
  septic shock and, 202–3
  stroke and, 203–4
Nitric oxide synthase, 191–211
  inhibition, 191–92, 197–211
    L-arginine analogues, 197–200, 202
    L-citrulline analogues, 200
    guanidine, 200
    indazoles, 201, 203–4
    mercapto-alkyl-guanidine, 198, 201
  isoforms, 192–95
  potential therapeutic use of selective inhibitors
  diabetes, 208–9
  inflammation, 205–7
  meningitis, 209
  migraine, 207–8
  neurodegeneration, 204–5
  nociception, 207
  septic shock, 202–3
  stroke, 203–4
  regulation of expression, 196
7-Nitroindazole
  nitric oxide synthase inhibition and, 198, 201, 203–4, 207
NMDA receptor
  glutamate expression and, 221–22, 231–34
Nociception
  therapeutic use of selective nitric oxide synthase inhibitors for, 207

O

Olfactory-specific transcription factor, 1
Oligodendrocytes, 151
Osteopontin
  oxidant-induced atherosclerosis and, 249, 256–58
Ovarian function
  pineal gland and, 54
Oxidative injury, 243–59
  AR receptor and, 246, 252–54
  c-Ha ras gene expression and, 243, 248, 251–56
  extracellular matrix and, 250, 256–58
  integrins and, 250–51
  osteopontin and, 256–58
Oxidative stres, 67–89
  protection against metallothionein and, 82–83

P

Pentanol, 127
Peroxisome proliferator–activated receptors (PPARs), 71
P-170 glycoproteins, 1
Phenothiazines, 380–81
Phenoxazine, 379
Phenylethanolamine N-methyltransferase (PNMT), 19, 39
Phospholipase A_2, 160, 175–85
  role in inflammation, 175–85
    antisense inhibition and, 184–85
    catalysis, 180
    cellular regulation, 180–81
    chemical inhibition, 175, 181–84
    eicosanoid biosynthesis and, 175–77
    sn-2 fatty acyl bond of phospholipids and, 175–76
Phospholipase D, 127
Phospholipids, 175–85
  phospholipase A_2 regulation and, 175–85
  sn-2 ester bond of, 175–76
Phosphatidylalcohols, 127, 129–30
Pineal gland, 53–62
  circadian biology of, 53–62
  melatonin production and, 53–62
    biosynthesis, 54–55
    CRX and, 57
    hydroxyindole-O-methyl-transferase and, 54–55
    pineal night-specific ATPase and, 56–57
    pineal regulatory element and, 56–57
    serotonin N-acetyltransferase and, 53–57
  See also Circadian rhythms; Melatonin
Pineal night-specific ATPase (PINA), 56–57
Pineal regulatory element (PIRE), 53, 56–57
Platelet-derived growth factor
  oxidant-induced atherosclerosis and, 247–48
Polycyclic aromatic hydrocarbons (PAHs)
  disease induced by cytochrome P4501A1 and, 104–19
Pregnenolone 16α-carbonitrile, 2
Prenylcysteines, 381–82
Propafenone-related compounds, 379
Propanol, 127–28
Pyridine nucleotides, 68

Q

Quinacrine, 380

R

Reactive oxygen species (ROS), 67–89, 132–33, 279–83

gene expression regulation by, 67–89
generation, 68–71
mitochondrial, 69–71
mitochondrial electron transport chain and, 68
nonmitochondrial, 71
metallothionein as trap for, 279–82
metal response element-binding transcription factor 1 and, 80–83
nitric oxide and, 67
short-chain alcohols and, 132–33, 139–42
signal transduction and, 71–80
AP-1 activation, 72–77, 79–80
AP-1 redox regulation, 73–74
NF-κB activation, 77–79
superoxide anion, 67
superoxide dismutases, 69, 79–80
hydroxyl radical, 69
singlet oxygen, 69, 79–80
Receptor genes, 221
Redox reactions, 243–59
oxidant-induced atherosclerosis and, 243–59
osteopontin signaling and, 256–58
Reduction/oxidation reactions
See Redox reactions
Reserpine, 378
Retinoic acid, 68, 399–421
13*cis* Retinoic acid, 400, 404–5
Retinoid receptor, 71, 399, 406–17, 421
activator of retinoid receptors (ACTR), 411
RARs, 410–17, 421
retinoid X receptor-β (RXRβ), 71
RXRs, 410–17, 421
Retinoids, 399–421
metabolic pathway, 406–11, 419
synthetic, 413–14
arotinoids, 413–14
retinamides, 413
teratogenic, 411–14
teratology of, 399–421
six principles of, 400–6
toxicokinetic parameters, 417–21
Retinoid X receptor-β, 71
Retinyl esters, 399
Rifampicin, 1, 3–4
cytochrome P-450 3A4 gene expression and, 1, 3–4

S

Schwann cells, 151, 166–68
neurotoxicity and, 151, 166–68
synaptic activity modulation, 167
Semicarbazide-sensitive amine reductase (SSAO), 247
Septic shock, 191, 202–3
therapeutic use of selective nitric oxide synthase inhibitors for, 191, 202–3
Serotonin
N-acetylation of melatonin synthesis and, 54–55
Serotonin N-acetyltransferase (NAT), 53–55, 62
diurnal variations in activity for, 55
melatonin synthesis and, 53–55
molecular cloning of, 55–56
Short-chain alcohols, 127–42
cytotoxity of, 127–42
cell proliferation and, 139–42
cell-specific toxicity and, 128–29
cytochrome P-4502E1 and, 132–33
fatty acid ethyl esters and, 127, 130–31
mitochondria and, 131, 133–39
phosphatidyl alcohol and, 129
reactive oxygen species and, 132–33, 139–42
Signal transduction
reactive oxygen species and, 67, 71–80
Smooth muscle cells
atherosclerosis and proliferation of vascular, 244–59
Staurosporine, 378
Stroke
therapeutic use of selective nictric oxide synthase inhibitors for, 191, 203–4
Sulfhydryl drugs
S-methylation of, 29–39
thioether methyltransferase, 19, 38–39
thiopurine methyltransferase, 29–38
Superoxide anion, 67, 69
Suprachiasmatic nucleus (SCN)
circadian rhythms and, 53, 57, 60, 61

T

Teratology, 399–421
of retinoids, 399–421
developmental stage of embryo at exposure, 402–3
dose-response relationship, 406
functional deficits, 404–5
genetic factors and, 400–2
rate and extent of exposure, 405–6
teratogenic mechanisms, 403–4
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), 103, 105–19
CYP1A1 gene expression and, 105–19
Thioether methyltransferase (TMT), 19, 38–39
S-methylation of, 38–39
6-Thioguanidine nucleotides, 30
Thiol methyltransferase, 19, 22
Thiopurine methyltransferase (TPMT), 20, 29–38, 40–41, 44–45
pharmacogenetics of, 29–38
alleles, 33
Tocopherols, 68
Traffic ATPases, 363
Transcription factors, 67–89, 221–29
glutamate receptor genes, 221–29
oxidative stress and gene expression, 67–89
Transcriptional regulation, 53, 55–56
serotonin N-acetyltransferase and, 55–56
Transgenic technology, 221, 231–35, 315
glutamate receptors, 221, 231–35
Translation
glutamate receptors, 221, 230–31

Traumatic brain injury, 157

U

UCN-01, 295, 306

V

Verapamil, 369, 375–77
Vitamin A
  dietary deficiency, 399
  embryogenesis and, 399–421
  excessive intake, 399
  teratogenesis and, 399–421

W

Wilson's disease, 274

X

Xerophthalmia, 399

Z

Zinc, 267–68, 272–86
  homeostasis, 267–68, 272–73, 283
  metallothionein and, 267–68, 272–86
    neurodegenerative disease and, 283–84
  teratogenesis and, 399–421

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 35–39

A

Acosta D Jr, 38:63–96
Alexander RW, 36:281–306
Allen JW, 39:151–73
Amara SG, 39:431–56
Ambudkar SV, 39:361–97
Anders MW, 38:501–37
Aposhian HV, 37:397–419
Aschner M, 39:151–73
Augustine GJ, 36:659–701

B

Baker RC, 39:127–50
Bakhle YS, 38:97–120
Balboa MA, 39:175–89
Balsinde J, 39:175–89
Barrett JC, 36:573–96
Bellamy WT, 36:161–83
Bennett CF, 36:107–29
Benovic JL, 38:289–319
Benowitz NL, 36:597–613
Bilsky EJ, 36:379–401
Black J, 36:1–33
Blaschke TF, 37:451–75
Borges K, 39:221–41
Borjigin J, 39:53–65
Botting RM, 38:97–120
Boyer JL, 35:541–79
Brett CM, 38:431–60
Briggs JM, 37:71–90
Briving C, 35:277–305
Burchiel SW, 36:131–59
Burns ME, 36:659–701
Burt SK, 36:545–71

C

Catterall WA, 37:361–96
Chao AC, 35:257–76
Chaudhuri G, 35:165–94; 37:477–515
Choudhuri S, 39:267–94
Clapham DE, 37:167–203
Collins MD, 39:399–430
Collman GW, 36:573–96
Conn PJ, 37:205–37
Cory-Slechta DA, 35:391–415
Costa E, 38:321–50
Costa LG, 38:21–43
Coyle JT, 36:83–106
Cronstein BN, 35:449–62
Crooke ST, 36:107–29
Croxatto HB, 36:47–81

D

Dalton TP, 39:67–101
Davila DR, 36:131–59
Davila JC, 38:63–96
Davis B, 35:341–68
DeBello WM, 36:659–701
Dekant W, 38:501–37
De Mey JGR, 35:501–39
Dennis EA, 39:175–89
Dessauer CW, 36:461–80
Dey S, 39:361–97
Dingledine R, 39:221–41
Dray A, 36:253–80
Dunham EW, 37:53–69

E

Erickson JW, 36:545–71
Evans CJ, 36:379–401
Exton JH, 36:481–509

F

Fan A, 35:341–68
Felder CC, 38:179–200
Felten DL, 35:417–48
Fisher JW, 38:1–20
Fukuto JM, 35:165–94
Furchgott RF, 35:1–27

G

Gardner P, 35:257–76
Giacomini KM, 38:431–60
Gibbs JB, 37:143–66
Gilman AG, 36:461–80
Glass M, 38:179–200
Goldstein A, 37:1–28
Gonzalez FJ, 35:369–90
Gottesman MM, 39:361–97
Griendling KK, 36:281–306
Gudermann T, 36:429–59
Guengerich FP, 39:1–17

H

Halmes NC, 37:91–117
Halpert JR, 35:29–53
Hammond HK, 39:343–60
Hankinson O, 35:307–40
Harden TK, 35:541–79
Harman AW, 35:129–44
Hefti F, 37:239–67
Heinrich M, 38:539–65
Hersey S, 35:277–305
Higgs A, 39:191–220
Hobbs AJ, 39:191–220
Hockerman GH, 37:361–96
Hoffman AR, 38:45–61
Holsapple MP, 36:131–59
Hosokawa M, 38:257–88
Howd R, 35:341–68
Howlett AC, 35:607–34
Hoyer PB, 36:307–31
Hrycyna CA, 39:361–97
Huff J, 36:573–96

I

Insel PA, 39:175–89, 343–60
Ito K, 38:461–99
Iwatsubo T, 38:461–99

J

Joad JP, 37:29–52
Johnson BD, 37:361–96
Johnson DG, 39:295–312
Jordan VC, 35:195–211

K

Kalkbrenner F, 36:429–59
Kaminski NE, 36:131–59
Kanamitsu S, 38:461–99
Karras JG, 36:131–59
Kastrissios H, 37:451–75
Kimelberg HK, 39:151–73
Klaassen CD, 39:267–94
Kobilka BK, 38:351–73
Korzekwa KR, 35:369–90
Kramer RE, 39:127–50
Krupnick JG, 38:0289–319

L

Lai J, 36:379–401
Lake BG, 35:483–507
Laskin DL, 35:655–77
Lasségue B, 36:281–306
Lau SS, 38:229–55
Lazo JS, 35:635–53
Ledbetter JA, 36:131–59
Lemasters JJ, 37:327–38
Le Moal M, 36:359–78
Li C, 36:185–201
Li X, 39:53–65
Liehr JG, 36:203–32
Lipton SA, 38:159–77
Liu J, 39:267–94
LoPachin RM, 39:151–73
Lukas SE, 36:333–57

M

Macdonald RL, 35:463–82
Madden KS, 35:417–48
Maines MD, 37:517–54
Mao GE, 39:399–430
Marcus R, 38:45–61
Marrone TJ, 37:71–90
Marton LJ, 35:55–91
Masaki T, 35:235–55
Maxwell MJ, 35:129–44
McCammon JA, 37:71–90
Melchert RB, 38:63–96
Meyer UA, 37:269–96
Miljanich GP, 35:707–34
Miller RJ, 38:201–27
Mirsalis JC, 35:145–64
Mombouli J-V, 35:679–705
Moncada S, 39:191–220
Monforte JA, 35:125–44
Monks TJ, 38:229–55
Myers MG Jr, 36:615–58
Myers SJ, 39:221–41

N

Nakajima Y, 38:461–99
Nathan L, 37:477–515
Neal RA, 36:35–46
Neer EJ, 37:167–203
Nicholas RA, 35:541–79

O

Olah ME, 35:581–606
Oliff A, 37:143–66
Ortiz de Montellano BR, 38:539–65
Otterness DM, 39:19–52

P

Pastan I, 39:361–97
Pegg AE, 35:55–91
Pendino KJ, 35:655–77
Peoples RW, 36:185–201
Peterson BZ, 37:361–96
Pettit DL, 36:659–701
Piazza PV, 36:359–78
Pin J-P, 37:205–37
Pinkerton KE, 37:29–52
Pitt BR, 35:635–53
Polson JB, 36:403–27
Porreca F, 36:379–401
Post SR, 39:343–60
Pratt WB, 37:297–326
Puga A, 39:67–101
Pumford NR, 37:91–117

R

Ramachandra M, 39:361–97
Ramachandran J, 35:707–34
Ramos KS, 39:243–65
Regunathan S, 36:511–44
Reis DJ, 36:511–44
Robbins A, 36:47–81
Robles M, 38:539–65
Rock DM, 35:463–82
Rodan GA, 38:375–88
Rodriguez E, 38:539–65
Rodriguez RJ, 38:63–96
Rohrer DK, 38:351–73

S

Sachs G, 35:277–305
Safe SH, 38:121–58
Sanders VM, 35:417–48
Satoh T, 38:257–88
Schatz AR, 36:131–59
Schieven GL, 36:131–59
Schultz G, 36:429–59
Schweizer FE, 36:659–701
Seal RP, 39:431–56
Shertzer HG, 39:67–101
Shin JM, 35:277–305
Sibley DR, 39:313–41
Simonian NA, 36:83–106
Sipes IG, 36:307–31
Smits JFM, 35:501–39
Snyder SH, 35:213–33; 39:53–65
Spitz IM, 36:47–81
Stiles GL, 35:581–606
Strada SJ, 36:403–27
Streit WJ, 39:151–73
Strosberg AD, 37:421–50
Struijker-Boudier HAJ, 35:509–39
Stuehr DJ, 37:339–59
Sugiyama Y, 38:461–99
Sunahara RK, 36:461–80
Szumlanski CL, 39:19–52

T

Thummel KE, 38:389–430
Thurman RG, 37:327–38

U

Urban L, 36:253–80

V

Vanderah TW, 36:379–401
Vane JR, 38:97–120
Vanhoutte PM, 35:679–705

W

Wagner JA, 35:257–76
Walker CL, 39:295–312
Wallmark B, 35:277–305
Wang CC, 35:93–127
Wei L-N, 37:119–41
Weight FF, 36:185–201
Weinshilboum RM, 39:19–52
Weissmann G, 35:449–62
West JE, 38:539–65
White MF, 36:615–58
Whitlock JP Jr, 39:103–25
Wilkinson GR, 38:389–430
Winegar RA, 35:145–64
Witschi H, 37:29–52
Wolff MS, 36:573–96
Woosley RL, 36:233–52

Y

Yager JD, 36:203–32

Z

Zaki PA, 36:379–401
Zanger UM, 37:269–96
Zhang J, 35:213–33
Zhang L, 38:431–60
Zimmerman BG, 37:53–69

CHAPTER TITLES, VOLUMES 35–39

PREFATORY

Pharmacology

A Research Trail Over Half A Century	RF Furchgott	35:1–27
A Personal View of Pharmacology	J Black	36:1–33
A Rewarding Research Pathway	A Goldstein	37:1–28
A Quest for Erythropoietin Over Nine Decades	JW Fisher	38:1–20

Toxicology

A Career in Toxicology	RA Neal	36:35–46

GENERAL TOPICS IN PHARMACOLOGY AND TOXICOLOGY

Receptors

The ARYL Hydrocarbon Receptor Complex	Oliver Hankinson	35:307–40
Polyamine Regulation of *N*-Methyl-D Aspartate Receptor Channels	DM Rock, RL Macdonald	35:463–82
P_2-Purinergic Receptors: Subtype-Associated Signaling Responses and Structure	TK Harden, JL Boyer, RA Nicholas	35:541–79
Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation	ME Olah, GL Stiles	35:581–606
Pharmacology of Cannabinoid Receptors	AC Howlett	35:607–34
Angiotensin Receptors and Their Therapeutic Implications	KK Griendling, B Lasségue, RW Alexander	36:281–306
Opioid Receptor Types and Subtypes: The δ Receptor as a Model	PA Zaki, EJ Bilsky, TW Vanderah, J Lai, CJ Evans, F Porreca	36:379–401
Diversity and Selectivity of Receptor-G Protein Interaction	T Gudermann, F Kalkbrenner, G Schultz	36:429–59
Imidazoline Receptors and Their Endogenous Ligands	S Regunathan, DJ Reis	36:511–44
Pharmacology and Functions of Metabotropic Glutamate Receptors	PJ Conn, J-P Pin	37:205–37
The Role of the hsp90-Based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling via Map Kinase	WB Pratt	37:297–326
Structure and Function of the β_3-Adrenergic Receptor	AD Strosberg	37:421–50
Cannabinoid Receptors and Their Endogenous Agonists	CC Felder, M Glass	38:179–200
Presynaptic Receptors	RJ Miller	38:201–27
From GABAA Receptor Diversity Emerges A Unified Vision of GABAergic Inhibition	E Costa	38:321–50
Insights from In Vivo Modification of Adrenergic Receptor Gene Expression	DK Rohrer, BK Kobilka	38:351–73
Genetic Regulation of Glutamate Receptor Ion Channels	SJ Myers, R Dingledine, K Borges	39:221–41
New Insights into Dopaminergic Receptor Function Using Antisense and Genetically Altered Animals	DR Sibley	39:313–41

Synaptic Functions

The Pharmacology of the Gastric Acid Pump: The H^+,K^+ ATPase	G Sachs, JM Shin, C Briving, B Wallmark, S Hersey	35:277–305
Antagonists of Neuronal Calcium Channels: Structure, Function, and Therapeutic Implications	GP Miljanich, J Ramachandran	35:707–34
Insulin Signal Transduction and the IRS Proteins	MG Myers Jr, MF White	36:615–58
Exocytosis: Proteins and Perturbations	GJ Augustine, ME Burns, WM DeBello, DL Pettit, FE Schweizer	36:659–701
Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels	GH Hockerman, BZ Peterson, BD Johnson, WA Catterall	37:361–96
Signal Transduction in Environmental Neurotoxicity	LG Costa	38:21–43
Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target	AJ Hobbs, A Higgs, S Moncada	39:191–220
Redox Regulation of *c-Ha-ras* and Osteopontin Signaling in Vascular Smooth Muscle Cells: Implications in Chemical Atherogenesis	KS Ramos	39:243–65
Cyclins and Cell Cycle Checkpoints	DG Johnson, CL Walker	39:295–312

Enzymes

Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition	JM Fukuto, G Chaudhuri	35:165–94
Complexity and Diversity of Mammalian Adenylyl Cyclases	RK Sunahara, CW Dessauer, AG Gilman	36:461–80
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins	JH Exton	36:481–509
The Heme Oxygenase System: A Regulator of Second-Messenger Gases	MD Maines	37:517–54
The Mammalian Carboxylesterases: From Molecules to Functions	T Satoh, M Hosokawa	38:257–88
The Role of Receptor Kinases and Arrestins in G Protein-Coupled Receptor Regulation	JG Krupnick, JL Benovic	38:289–319
Methylation Pharmacogenetics: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase	RM Weinshilboum, DM Otterness, CL Szumlanski	39:19–52
Regulation and Inhibition of Phospholipase A_2	J Balsinde, MA Balboa, PA Insel, EA Dennis	39:175–89

Chemical Agents

Polyamines as Targets for Therapeutic Intervention	LJ Marton, AE Pegg	35:55–91
Mechanisms of Hepatocarcinogenicity of Peroxisome-Proliferating Drugs and Chemicals	BG Lake	35:483–507
Progress in Antisense Oligonucleotide Therapeutics	ST Crooke, CF Bennett	36:107–29
Pharmacology of Nicotine: Addiction and Therapeutics	NL Benowitz	36:597–613
Protein Targets of Xenobiotic Reactive Intermediates	NR Pumford, NC Halmes	37:91–117
G Protein Beta-Gamma Subunits	DE Clapham, EJ Neer	37:167–203
Pharmacology of Neurotrophic Factors	F Hefti	37:239–67

Structure-Function Aspects in the Nitric Oxide Synthases	DJ Stuehr	37:339–59
Enzymatic Methylation of Arsenic Species and Other New Approaches to Arsenic Toxicity	HV Aposhian	37:397–419
The Pharmacology and Toxicology of Polyphenolic-Glutathione Conjugates	TJ Monks, SS Lau	38:229–55
Ethnopharmacology of Mexican Asteraceae (Compositae)	M Heinrich, M Robles, JE West, BR Ortiz de Montellano, E Rodriguez	38:539–65
The Pineal Gland and Melatonin: Molecular and Pharmacologic Regulation	J Borjigin, X Li, SH Snyder	39:53–65
Regulation of Gene Expression by Reactive Oxygen	TP Dalton, HG Shertzer, A Puga	39:67–101
Cytotoxicity of Short-Chain Alcohols	RC Baker, RE Kramer	39:127–50
Metallothionein: An Intracellular Protein to Protect Against Cadmium Toxicity	CD Klaassen, J Liu, S Choudhuri	39:267–94
Teratology of Retinoids	MD Collins, GE Mao	39:399–430
Biotransformation		
Structural Basis of Selective Cytochrome P450 Inhibition	JR Halpert	35:29–53
Cytochromes P450 Expression Systems	FJ Gonzalez, KR Korzekwa	35:369–90
Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism	UA Meyer, UM Zanger	37:269–96
In Vitro and In Vivo Drug Interactions Involving Human CYP3A	KE Thummel, GR Wilkinson	38:389–430
Glutathione-Dependent Bioactivation of Haloalkenes	MW Anders, W Dekant	38:501–37
Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism	FP Guengerich	39:1–17
Induction of Cytochrome P4501A1	JP Whitlock Jr	39:103–25
Pharmacokinetics/Toxicokinetics		
Role of Organic Cation Transporters in Drug Absorption and Elimination	L Zhang, CM Brett, KM Giacomini	38:431–60
Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter	SV Ambudkar, S Dey, CA Hrycyna, M Ramachandra, I Pastan, MM Gottesman	39:361–97
Cancer and Carcinogenesis		
Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer	VC Jordan	35:195–211
Metallothioneins and Cell Death by Anticancer Drugs	JS Lazo, BR Pitt	35:635–53
P-Glycoproteins and Multidrug Resistance	WT Bellamy	36:161–83
Molecular Mechanisms of Estrogen Carcinogenesis	JD Yager, JG Liehr	36:203–32
The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics	JB Gibbs, A Oliff	37:143–66
Interactions Between Hormones and Chemicals in Breast Cancer	SH Safe	38:121–58
Clinical Therapeutics		
Molecular Strategies for Therapy of Cystic Fibrosis	JA Wagner, AC Chao, P Gardner	35:257–76
Medication Compliance as a Feature in Drug Development	H Kastrissios, TF Blaschke	37:451–75

Drug Development Science

Structure-Based Drug Design: Computational Advances	TJ Marrone, JM Briggs, JA McCammon	37:71–90

SYSTEMS

Immune System/Inflammation

Catecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness	KS Madden, VM Sanders, DL Felten	35:417–48
Targets for Antiinflammatory Drugs	BN Cronstein, G Weissmann	35:449–62
Macrophages and Inflammatory Mediators in Tissue Injury	DL Laskin, KJ Pendino	35:655–77
Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers	MP Holsapple, JG Karras, JA Ledbetter, GL Schieven, SW Burchiel, DR Davila, AR Schatz, NE Kaminski	36:131–59
Cyclooxygenases 1 and 2	JR Vane, YS Bakhle, RM Botting	38:97–120

Central Nervous System

Nitric Oxide in the Nervous System	J Zhang, SH Snyder	35:213–33
Relationships Between Lead-Induced Learning Impairments and Changes in Dopaminergic, Cholinergic, and Glutamatergic Neurotransmitter System Functions	DA Cory-Slechta	35:391–415
Oxidative Stress in Neurodegenerative Diseases	NA Simonian, JT Coyle	36:83–106
Lipid vs Protein Theories of Alcohol Action in the Nervous System	RW Peoples, C Li, FF Weight	36:185–201
New Pharmacological Strategies for Pain Relief	A Dray, L Urban	36:253–80
CNS Effects and Abuse Liability of Anabolic-Androgenic Steroids	SE Lukas	36:333–57
Pathophysiological Basis of Vulnerability to Drug Abuse: Role of an Interaction Between Stress, Glucocorticoids, and Dopaminergic Neurons	PV Piazza, M Le Moal	36:359–78
Glial Cells in Neurotoxicity Development	M Aschner, JW Allen, HK Kimelberg, RM LoPachin, WJ Streit	39:151–73
Excitatory Amino Acid Transporters: A Family in Flux	RP Seal, SG Amara	39:431–56

Autonomic Nervous System

β-Adrenergic Receptors and Receptor Signaling in Heart Failure	SR Post, HK Hammond, PA Insel	39:343–60

Cardiovascular System

Possible Role of Endothelin in Endothelial Regulation of Vascular Tone	T Masaki	35:235–55
Pharmacology of Cardiac and Vascular Remodeling	HAJ Struijker-Boudier, JFM Smits, JGR De Mey	35:509–39
Kinins and Endothelial Control of Vascular Smooth Muscle	J-V Mombouli, PM Vanhoutte	35:679–705
Cardiac Actions of Antihistamines	RL Woosley	36:233–52
Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle	JB Polson, SJ Strada	36:403–27
Tissue Renin-Angiotensin Systems: A Site of Drug Action?	BG Zimmerman, EW Dunham	37:53–69

Reperfusion Injury After Liver Preservation for Transplantation	JJ Lemasters, RG Thurman	37:327–38
Endocrine System		
Antiprogestins: Mechanism of Action and Contraceptive Potential	IM Spitz, HB Croxatto, A Robbins	36:47–81
Assessment of Follicle Destruction in Chemical-Induced Ovarian Toxicity	PB Hoyer, IG Sipes	36:307–31
Estrogens and Atherosclerosis	L Nathan, G Chaudhuri	37:477–515
Growth Hormone As Therapy for Older Men and Women	R Marcus, AR Hoffman	38:45–61
Mechanism of Action of Biophosphates	GA Rodan	38:375–88
Pulmonary System		
The Toxicology of Environmental Tobacco Smoke	H Witschi, JP Joad, KE Pinkerton	37:29–52
Microbial Systems		
Molecular Mechanisms and Therapeutic Approaches to the Treatment of African Trypanosomiasis	CC Wang	35:93–127
Structural Mechanisms of HIV Drug Resistance	JW Erickson, SK Burt	36:545–71
Neuronal Injury Associated with HIV-1: Approaches to Treatment	SA Lipton	38:159–77
MISCELLANEOUS		
Techniques		
An Evaluation of the Role of Calcium in Cell Injury	AW Harman, MJ Maxwell	35:129–44
Transgenic Animal Models for Detection of In Vivo Mutations	JC Mirsalis, JA Monforte, RA Winegar	35:145–64
Transgenic Animals as New Approaches in Pharmacological Studies	L-N Wei	37:119–41
Predictive Value of In Vitro Model Systems in Toxicology	JC Davila, RJ Rodriguez, RB Melchert, D Acosta Jr	38:63–96
Quantitative Prediction of In Vivo Drug Clearance and Drug Interactions from In Vitro Data on Metabolism, and Together with Binding and Transport	K Ito, T Iwatsubo, S Kanamitsu, Y Nakajima, Y Sugiyama	38:461–99
Risk Assessment		
Risk Assessment of Environmental Chemicals	A Fan, R Howd, B Davis	35:341–68
Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings	MS Wolff, GW Collman, JC Barrett, J Huff	36:573–96